| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | 10 mg/ml concentrate for solution for infusion |
| Reference number | 2736 |
| Indication | Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/10/2015 |
| NICE guidance | TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |